Inflammation & Tissue Injury

New approaches for managing inflammation

Inflammation is a fundamental biological process and an essential component of the body’s defense and repair systems, protecting against infection and injury. When tightly regulated, it is essential for health, orchestrating immune defense and tissue repair. However, when inflammation becomes excessive, persistent, or dysregulated, it drives disease rather than resolution. Pathologic inflammation underlies a wide range of serious conditions, from chronic respiratory diseases to cardiovascular, metabolic, and autoimmune disorders, representing one of the most significant unmet needs in modern medicine. Current therapeutic options often rely on broad immunosuppression, which can blunt host defense and fail to address the underlying pathogenic pathways. There is a critical need for new approaches that selectively modulate maladaptive inflammation while preserving protective immunity.

Our initial focus is on pulmonary diseases, where the consequences of dysregulated inflammation are especially devastating. In the lung, maladaptive inflammation drives epithelial and endothelial injury, airway remodeling, fibrosis, and recurrent infections, leading to progressive loss of lung function, high morbidity and mortality, and significant healthcare burden worldwide. By targeting the central inflammatory mechanisms underlying these processes, zelpultide alfa has the potential to transform outcomes in patients with serious lung disease. Importantly, the same biology that drives inflammation in the lung is also implicated in multiple other disease areas in multiple tissues and organs, creating the opportunity for broad therapeutic impact across diverse indications.